Has Tabatha Mize received payments from drug or device companies?

Yes. Drug and device makers reported $2,525 in general payments to Tabatha Mize across 156 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tabatha Mize did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tabatha Mize come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tabatha Mize

Family · Porter, TXNPI 1114438199

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 38.9% of the total. 2025 is the largest year on record at $716, more than ten times the $69 reported in 2021.

$2,525in general payments, 2019–2025

Across 156 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$983
Amgen$205
Lilly USA, LLC$118
Soleno Therapeutics, Inc.$105
Idorsia Pharmaceuticals US Inc$104
Esperion Therapeutics, Inc.$103
plus $907 from 20 others

What the payments were for

Food & beverage$2,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	70	$983
Amgen	11	$205
Lilly USA, LLC	7	$118
Soleno Therapeutics, Inc.	5	$105
Idorsia Pharmaceuticals US Inc	6	$104
Esperion Therapeutics, Inc.	6	$103
AstraZeneca	6	$97
Novartis	5	$85
Organon	2	$82
Abbott	4	$74
Takeda Pharmaceuticals U.S.A., Inc.	4	$63
Tolmar, Inc.	4	$58
Otsuka America Pharmaceutical, Inc.	3	$57
Avanir Pharmaceuticals, Inc.	3	$56
Dexcom, Inc.	3	$53
Biohaven Pharmaceutical Holding Company Ltd.	3	$46
Pfizer	2	$38
GSK	2	$32
Exact Sciences	2	$31
Antares Pharma, Inc.	2	$29
Sanofi-aventis U.S. LLC	1	$20
Novo Nordisk	1	$19
Verity Pharmaceuticals Inc.	1	$19
Boehringer Ingelheim	1	$16
Paratek Pharmaceuticals, Inc.	1	$16
Axsome Therapeutics, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QULIPTA$125
UBRELVY$125

How this compares

$2,525 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Other family in Porter

David WeirDallas$959K
Robin BeachHouston$428K
April LopezMcAllen$417K
Sarah AguilarHouston$199K
Sie ThomasDallas$197K
Anna CastroSan Antonio$184K
Jill CampbellShenandoah$182K
Angela AchaPflugerville$174K
Susan BowlinIrving$164K
Stephanie RodriguezCorpus Christi$159K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →